Insulin Delivery Route for the Artificial Pancreas: Subcutaneous, Intraperitoneal, or Intravenous? Pros and Cons
Open accessThe DOI matches its Crossref record.
Abstract
Insulin delivery is a crucial component of a closed-loop system aiming at the development of an artificial pancreas. The intravenous route, which has been used in the bedside artificial pancreas model for 30 years, has clear advantages in terms of pharmacokinetics and pharmacodynamics, but cannot be used in any ambulatory system so far. Subcutaneous (SC) insulin infusion benefits from the broad expansion of insulin pump therapy that promoted the availability of constantly improving technology and fast-acting insulin analog use. However, persistent delays of insulin absorption and action, variability and shortterm stability of insulin infusion from SC-inserted catheters generate effectiveness and safety issues in view of an ambulatory, automated, glucose-controlled, artificial beta cell. Intraperitoneal insulin delivery, although still marginally used in diabetes care, may offer an interesting alternative because of its more-physiological plasma insulin profiles and sustained stability and reliability of insulin delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Insulin delivery methods: Past, present and future
Shah, R., Shah, V., Patel, M., & Maahs, D. (2016) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.176456 · Cited by 287
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Gingras, V., Taleb, N., Roy‐Fleming, A., Legault, L., & Rabasa‐Lhoret, R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13052 · Cited by 113
“The intra-peritoneal insulin infusion route is technically challenging but advantageous in terms of pharmacokinetics for glucose regulation as compared with the subcutaneous route because insulin is delivered mainly in the portal vein rather than systemically, which is far closer to normal physiology, allowing a large…”
Evolution of Devices in Diabetes Management
Penfornis, A., Personeni, E., & Borot, S. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0058 · Cited by 49
“66 Historically, this combination was made available by the development of the bedside external artificial pancreas in the 1970s: the Bio-stator (cid:2) (Miles Laboratories, Elkhart, IN).”
Influential
Metadata
- Authors
- Renard, E.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2008-07
- Volume
- 2
- Issue
- 4
- Pages
- 735-738
- ISSN
- 1932-2968 (ISSN-L)
- OpenAlex
- W2150844040
- Cited by
- 66
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin Delivery Route for the Artificial Pancreas: Subcutaneous, Intraperitoneal, or Intravenous? Pros and Cons. https://app.cochat.ai/papers/10.1177/193229680800200429
- The paper
- Renard, E. (2008). Insulin Delivery Route for the Artificial Pancreas: Subcutaneous, Intraperitoneal, or Intravenous? Pros and Cons. Journal of Diabetes Science and Technology. https://doi.org/10.1177/193229680800200429
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.